LTGO (Latigo Biotherapeutics) OCF Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTGO Latigo Biotherapeutics Inc LTGO
8 GF Score
Price $18.56
View Full Analysis

What is Latigo Biotherapeutics OCF Margin %?

Latigo Biotherapeutics LTGO +1.70% 8 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates LTGO with a GF Score™ of 8/100. Among 953 Biotechnology companies, Latigo Biotherapeutics ranks worse than 104931.69% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Latigo Biotherapeutics's Cash Flow from Operations for the six months ended in Dec. 2025 was $-97.56 Mil. Latigo Biotherapeutics's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Latigo Biotherapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Latigo Biotherapeutics's current OCF Yield % is -320,800.00%.

The historical rank and industry rank for Latigo Biotherapeutics's OCF Margin % or its related term are showing as below:


LTGO's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.98
* Ranked among companies with meaningful OCF Margin % only.

Latigo Biotherapeutics OCF Margin % Related Terms

Latigo Biotherapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Latigo Biotherapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Latigo Biotherapeutics OCF Margin % Chart

Latigo Biotherapeutics Annual Data
Trend Dec24 Dec25
OCF Margin %
0.00 0.00

Latigo Biotherapeutics Semi-Annual Data
Dec24 Dec25
OCF Margin % 0.00 0.00
LTGO
8GF Score
Latigo Biotherapeutics Inc LTGO
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Latigo Biotherapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Latigo Biotherapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-97.557/0
= %

Latigo Biotherapeutics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-97.557/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Latigo Biotherapeutics (LTGO) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Latigo Biotherapeutics and its competitors. According to the industry distribution chart, Latigo Biotherapeutics ranks #999999 out of 953 companies in the Biotechnology industry.
Is Latigo Biotherapeutics' OCF Margin % too high?
Latigo Biotherapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Latigo Biotherapeutics ranks #999999 out of 953 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Latigo Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Latigo Biotherapeutics' OCF Margin % compare to ?
According to the Biotechnology industry distribution chart, Latigo Biotherapeutics ranks #999999 out of 953 companies for OCF Margin %. This places Latigo Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Latigo Biotherapeutics and its competitors. Latigo Biotherapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Latigo Biotherapeutics stock overvalued right now?
Latigo Biotherapeutics (LTGO) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Latigo Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Latigo Biotherapeutics (LTGO), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Latigo Biotherapeutics Business Description

Comparable Companies
Address 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA, USA, 91320
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
8GF Score

Get the complete analysis for LTGO

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.56
Price